An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Overall, global Stelara sales dropped 14.7% year-over-year to roughly $2.3 billion in 2024’s fourth quarter. For the full 12-month earnings period, Stelara sales slipped around 4.6% to $10.4 ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...

Investors are watching biosimilar competition with immunology drug Stelara, which extended to the key US market in January. We assume a more than $3 billion decline in global Stelara sales in 2025.

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

BECKLEY, W.Va. — An FBI chemist who tested a vial found in accused murderer Natalie Cochran’s refrigerator after the death of her husband testified Friday what was in the vial was consistent ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Support from readers like you keeps The Journal open. You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to ...

Bimekizumab – an IL-17A and IL-17F inhibitor – outdid both placebo and IL-12/IL-23 blocker Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...